Catalyst Pharmaceuticals (CPRX) Cost of Revenue (2019 - 2026)

Catalyst Pharmaceuticals (CPRX) has 8 years of Cost of Revenue data on file, last reported at $14.5 million in Q1 2026.

• Quarterly Cost of Revenue fell 19.18% year-over-year to $14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83.8 million (up 12.91% YoY) and the FY2025 annual result came in at $87.3 million, up 26.74% from the prior year.
• Cost of Revenue retreated to $14.5 million in Q1 2026, from $26.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $26.1 million in Q4 2025 to a low of $5.9 million in Q1 2022.
• A 5-year average of $15.1 million and a median of $14.5 million in 2026 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue soared 82.02% — and 2026, when it declined 19.18%.
• Tracing CPRX's Cost of Revenue over 5 years: stood at $11.2 million in 2022, then surged by 41.21% to $15.8 million in 2023, then surged by 36.9% to $21.6 million in 2024, then climbed by 20.47% to $26.1 million in 2025, then slumped by 44.48% to $14.5 million in 2026.
• The last three Cost of Revenue figures came in at $14.5 million (Q1 2026), $26.1 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.